Daxor Corporation (DXR)
| Market Cap | 56.35M +48.3% |
| Revenue (ttm) | 26,688 -77.7% |
| Net Income | 9.17M +1,609.7% |
| EPS | 1.81 +1,567.3% |
| Shares Out | 5.83M |
| PE Ratio | 5.34 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,265 |
| Open | 10.07 |
| Previous Close | 9.26 |
| Day's Range | 9.50 - 10.07 |
| 52-Week Range | 8.45 - 14.76 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 22.50 (+136.84%) |
| Earnings Date | Aug 28, 2026 |
About DXR
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Financial Performance
In 2025, Daxor's revenue was $26,688, a decrease of -77.71% compared to the previous year's $119,714. Earnings were $9.17 million, an increase of 1609.71%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DXR stock is "Buy." The 12-month stock price target is $22.5, which is an increase of 136.84% from the latest price.
News
Daxor Proxy statement: Proxy filing
Daxor filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Daxor trading halted, volatility trading pause
13:58 EDT Daxor (DXR) trading halted, volatility trading pause
Daxor issued patent from USPTO for absolute blood volume monitoring
Daxor (DXR) announced that the United States Patent and Trademark Office, or USPTO, has issued U.S. Patent No. 12,635,917 B2, titled “Remote Blood Volume Monitor.” The newly issued patent covers…
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
New Technology Expands Daxor's Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polyc...
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (...
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Oak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new ...
Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accur...
Daxor to showcase next-gen portable BVA at ACC.26 session
Daxor (DXR) Corporation announces its participation as an exhibitor at the American College of Cardiology Annual Scientific Session in New Orleans, LA, March 28-30, 2026. Daxor will showcase its new,…
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the Am...
Daxor Transcript: IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026
A direct blood volume analysis technology is driving improved patient outcomes and cost savings, with a new portable analyzer and expanded commercial reach. Revenue grew 45% in 2025, supported by strong partnerships, a recent capital raise, and a robust IP portfolio.
Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress
Daxor (DXR) Corporation will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine 2026 Critical Care Congress at McCormick Place in Chicago, IL, from March…
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in ...
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will par...
Daxor Slides: Corporate presentation
Daxor has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Daxor Earnings release: Q4 2025
Daxor released its Q4 2025 earnings on March 3, 2026, summarizing the period's financial results.
Daxor issues update in Letter to Shareholders
Daxor (DXR) issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 2, 2026 from CEO & President, Michael Feldschuh.
Daxor reports NAV per share of $9.07
The company said, “The most significant corporate highlight of the year was the receipt of FDA 510(k) clearance in August 2025 for Daxor’s (DXR) next-generation rapid, compact, and portable Blood…
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), ...
Daxor continues strategic expansion, opens new BVA program in Tennessee
Daxor (DXR) Corporation continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. “Th...
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
Expansion Leverages Daxor's ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global lea...
Daxor initiated with a Buy at Lake Street
Lake Street initiated coverage of Daxor (DXR) with a Buy rating and $23 price target calling it an “overlooked high-growth MedTech diagnostic company addressing a multi-billion-dollar” total addressab...
Daxor to transition to Securities Exchange Act of 1934 reporting company
Daxor (DXR) Corporation announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, subject to its…
Daxor prices 765,958 shares at $11.75 in registered direct offering
Daxor (DXR) Corporation entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock at a purchase price…
Daxor Corporation Announces $9 Million Registered Direct Offering
OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors...